Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Congress 2022 | Changing clinical trial endpoints in MPNs & the link between hematopoietic fitness and outcomes

Joseph Scandura • 31 Oct 2022
MPN Congress 2022
Myeloproliferative Neoplasms

Joseph Scandura, MD, PhD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, emphasizes the need to change the endpoints that are currently used in clinical trials for myeloproliferative neoplasms (MPNs) to focus on survival measures, discussing the potential of hematopoietic fitness as a marker of event risk. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joseph Scandura

Are megakaryocytes the root of MPN evils?
Joseph Scandura • 24 Nov 2022
2:13
The role of BMT & clinical trials in patients with PV with multiple treatment-limiting toxicities
Joseph Scandura • 31 Oct 2022
1:47
The central role of megakaryocytes in MPN pathophysiology
Joseph Scandura • 31 Oct 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals